reports
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Jacob Mekhael
Zealand Pharma Establishes Boston research hub
Zealand announced the establishment of a new research hub in Cambridge, Massachusetts, in the greater Boston area. The facility will serve as Zealand Pharma's primary US address and is expected to be operational from September 2026. Zealand Pharma's Cambridge hub will enhance the company's research platform through AI-driven drug discovery, advanced automation, and next-generation molecule creation, accelerating the translation of scientific insight into innovative medicines. The establishment o...
Zealand Pharma Establishes U.S. Research Hub in Cambridge, Massachuset...
Zealand Pharma Establishes U.S. Research Hub in Cambridge, Massachusetts to Expand Drug Discovery Capabilities and Accelerate Medicine Creation Press release – No. 6 / 2026 Zealand Pharma Establishes U.S. Research Hub in Cambridge, Massachusetts to Expand Drug Discovery Capabilities and Accelerate Medicine Creation New research hub in Cambridge, Massachusetts, in the greater Boston area, expands global discovery capabilities, combining Zealand Pharma’s more than 25 years of expertise in peptides and metabolic health with Boston’s biotech innovation ecosystem. Copenhagen, Denmark and B...
Zealand Pharma increases its share capital as a result of the exercise...
Zealand Pharma increases its share capital as a result of the exercise of employee warrants Company announcement – No. 4 / 2026 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, March 19, 2026 – Zealand Pharma A/S (“Zealand Pharma”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has by decision of the Board of Directors increased its share capital by a nominal amount of DKK 10,530 divided into 10,530 new shares with ...
Zealand Pharma to participate in upcoming investor conferences in Marc...
Zealand Pharma to participate in upcoming investor conferences in March 2026 Press release – No. 5 / 2026 Zealand Pharma to participate in upcoming investor conferences in March 2026 Copenhagen, Denmark, March 9, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced that the company will participate in the following investor conferences in March 2026. 2026 Jefferies Biotech on the Beach Summit, March 9-11 in Miami Adam Steensberg, President and Chief Executive Officer, will host investor meetings...
- BC-bc user
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Livio Luyten
- Lynn Hautekeete
- Michiel Declercq
- Wim Lewi
- Jacob Mekhael
Zealand Pharma Petrelintide shows modest weight loss but excellent tol...
Zealand reported mixed results from the phase 2 (ZUPREME-1) trial of petrelintide in overweight/obesity, showing a modest 10.7% weight loss at 42 weeks, while demonstrating excellent tolerability. We think this outcome makes first line positioning difficult, and view petrelintide as better suited for weight loss maintenance (subject to positive data in that setting). We adjust our peak sales estimate to $ 7b (from $ 22b), which brings down our TP to DKK 500 (from DKK 960). Given the lower upside...
Zealand Pharma announces positive Phase 2 results for petrelintide, an...
Zealand Pharma announces positive Phase 2 results for petrelintide, an amylin analog with potential to redefine the weight management experience for people living with overweight and obesity Company announcement – No. 3 / 2026 Zealand Pharma announces positive Phase 2 results for petrelintide, an amylin analog with potential to redefine the weight management experience for people living with overweight and obesity Petrelintide achieved up to 10.7% mean body weight reduction at week 42 (versus 1.7% with placebo) and demonstrated placebo-like tolerabilityAt the maximally effective dose, the...
Zealand Pharma convenes its Annual General Meeting 2026
Zealand Pharma convenes its Annual General Meeting 2026 Company announcement – No. 2 / 2026 Zealand Pharma convenes its Annual General Meeting 2026 Copenhagen, Denmark, February 19, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, hereby convenes its Annual General Meeting 2026. The Board of Directors of Zealand Pharma A/S hereby convenes the Annual General Meeting of the Company to be held on: Thursday, 26 March 2026 at 03:00 PM (CET) / 9:00 (ET) The Annual General Meet...
- Mathijs Geerts Danau
Zealand Pharma FY25 results: Looking forward to petrelintide phase 2 d...
Zealand reported FY25 results, ending the year with cash of DKK 15,109m (YE24: DKK 9,022m), reinforcing the strong balance sheet. OPEX increased to DKK 2,101m (FY24: 1,324m) driven by increased R&D spending related to the ongoing petrelintide phase 2 trials. For FY26, Zealand guides OPEX of DKK 2,700-3,300m, due to continued investment in the petrelintide franchise. We look forward to the read-out of the petrelintide phase 2 trial in obesity expected in 1Q26, which could confirm petrelintide's p...
- Guy Sips
- Hilde Van Boxstael
- Kristof Samoy
- Mathijs Geerts Danau
- Michiel Declercq
- Thibault Leneeuw
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
Zealand Pharma Announces Financial Results for the Full Year 2025
Zealand Pharma Announces Financial Results for the Full Year 2025 Company announcement – No. 1 / 2026 Zealand Pharma Announces Financial Results for the Full Year 2025 2025 marked a quantum leap for Zealand Pharma, with a transformative partnership for petrelintide, strong clinical progress, and organizational readiness, setting the stage for catalyst-rich and defining 2026 Entered a historic and transformative collaboration and license agreement with Roche to unlock the full potential of petrelintide as a future foundational therapy for weight management, aiming to establish the leading...
- Mathijs Geerts Danau
Zealand Pharma Positive phase 1a data for Kv1.3 channel blocker
Zealand Pharma reported positive phase 1a topline results for the Kv1.3 channel blocker ZP9830. Single ascending doses of ZP9830 were well tolerated, with no serious or severe adverse events or dose-limiting safety findings, and PK/PD profile was in-line with predictions. We view these data as de-risking for the program and look forward to the MAD data expected in 2H26, which should provide insight into extended exposure and additional proof of mechanism. Given the selective expression of Kv1.3 ...
- Guy Sips
- Lynn Hautekeete
- Mathijs Geerts Danau
- Thibault Leneeuw
- Thomas Couvreur
- Wim Hoste
Zealand Pharma announces positive Phase 1a topline results with Kv1.3 ...
Zealand Pharma announces positive Phase 1a topline results with Kv1.3 channel blocker ZP9830 Press release – No. 4 / 2026 Zealand Pharma announces positive Phase 1a topline results with Kv1.3 channel blocker ZP9830 Single doses of ZP9830 were well tolerated, with no serious or severe adverse events or dose-limiting safety findings observed at any dose levelZP9830 exhibited a pharmacokinetic profile in line with predictions based on preclinical data, and exploratory pharmacodynamic biomarkers showed robust, dose-dependent activity consistent with Kv1.3 target engagementZP9830 is a highly p...
Zealand Pharma conference call on February 19 at 2pm CET (8am ET) to p...
Zealand Pharma conference call on February 19 at 2pm CET (8am ET) to present full year 2025 financial results Press Release – No. 3 / 2026 Zealand Pharma conference call on February 19 at 2pm CET (8am ET) to present full year 2025 financial results Copenhagen, Denmark, February 12, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, announced that it will host a conference call on February 19, 2026, at 2:00 pm CET (8:00 am ET) following the announcement of financial results for the full year of 2025. Participat...
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Mathijs Geerts Danau
- Wim Lewi
- Jacob Mekhael
Zealand Pharma Model update, multiple important catalysts ahead
We update our Zealand model following the company's recent CMD held in December 2025. Zealand outlined its plans to become a generational metabolic health company, as well as sharing clear targets with 5 product launches in the next 5 years, and to have 10+ clinical programs by 2030. Our model update incorporates adjusted milestone timing from Roche, removes dapiglutide, as well as a few small tweaks on the rare disease pipeline. All in all, this brings us to a new TP of DKK 960 (from DKK 1,120)...
- Hilde Van Boxstael
- Mathijs Geerts Danau
- Wim Lewi
- Jacob Mekhael
Zealand Pharma Enters agreement with DCAI to use AI supercomputer for ...
Zealand announced that it entered into an agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support its Metabolic Frontier 2030 strategy, to deliver five launches, +10 clinical pipeline programs, and industry-leading cycle times from idea to clinic by 2030.The platform supports advanced characterization, simulation, and generative AI modelling for drug discovery and design. Financial terms were not disclosed. DKK 1,120 TP and BUY maintained.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.